6-K ·Filed Jun 22, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001575872-26-000428
Notable filing: 6-K
Actionable Insight • Neutral

Routine ESOP exercise disclosure — no trading signal. Monitor next 20-F or earnings release for fundamental updates on revenue, margins, and regulatory pipeline.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
RDY ▼ -9.42% at T+20d
NEUTRAL call ✗ call lost -9.42% · α vs SPY -9.27% · entry $13.91 → $12.60
Next anchor: T+60d due 16d ago
Latest observation: T+58 -12.12% FF3 residual α
Entry anchored
Jun 18, 03:59 PM ET
via exchange tick
T+1d
+2.88%
call +2.88% · α +4.33%
$14.31
settled 3mo ago
T+5d
+6.83%
call +6.83% · α +7.29%
$14.86
settled 3mo ago
T+20d
-9.42%
call -9.42% · α -9.27%
$12.60
settled 2mo ago
T+60d
—
call — · α —
—
due 16d ago

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's filed a routine 6-K disclosing a small equity allotment of 6,730 shares upon exercise of employee stock options under existing ESOP schemes. This is a standard administrative disclosure with no new material financial, operational, or regulatory information.

Key Facts

  • Allotted 6,730 equity shares of Re.1 each on June 19, 2026 to eligible employees exercising stock options under Dr. Reddy's Employees Stock Option Scheme, 2002 and Dr. Reddy's Employees ADR Stock Option Scheme, 2007.
  • Exercise prices were Re.1 (2,455 shares), Rs.562.80 (2,000 shares), and Rs.735.80 (2,275 shares) per share.
  • Total issued shares post-allotment: 83,46,76,800 equity shares of Re.1 each, representing a negligible 0.008% increase from prior outstanding.
  • No lock-in restrictions; shares rank pari passu with existing equity.

Financial Impact

Minimal dilution of approximately 0.008% of outstanding shares; aggregate proceeds from exercises are immaterial relative to the company's $11.7B market cap.

dilution

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000428
Document: 0001575872-26-000428-index.html0001575872-26-000428
Document: 0001575872-26-000428.txt0001575872-26-000428
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access